Northwest Biotherapeutics (NWBO) Corrects From the Peak: Now What?

The Northwest Biotherapeutics (OTC: NWBO) stock has been in focus among investors for quite some time and on Friday, it rallied after the company announced its financial results for the third quarter.

It should be noted that the stock had been trading at only $0.21 a share around a year ago but on Friday it closed at $1.35 a share. Northwest, which is best known for developing cancer-related medicines, suffered a loss of as much as $194.1 million in the third quarter.

Related:  Is Senseonics (SENS) Stock a Good Investment Play?

However, investors seemed to have shrugged it off. The Northwest stock rallied by as much as 3% on the back of the announcement from the company. The loss per share for the period stood at $0.26. However, once adjusted for extinguished debt and non-recurring costs, the loss per share came down to $0.07.

The total revenues for the quarter came in at $216,000. Considering the latest price action in the stock, it might be a good idea for investors to keep an eye on Northwest.

Related:  Regen BioPharma (RGBP) Rockets Suddenly On Huge Volume: What's Going On?

Michael Rowels

Weekend Contributor. Writing for business and finance publishers has become his passion over the last decades after he completed a master's degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.